Clinical trials: Restenosis
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
Femoropopliteal In-Stent Restenosis
First in Human Study of Winsor Laser Catheter: A Prospective Registry to Evaluate The Safety and Performance of the Winsor Laser Catheter in the Treatment of In-Stent Restenosis
The study will evaluate the procedural safety and efficacy of the Winsor Laser Catheters for the treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
- Trial name
- NCT01962389
- Testing
- Winsor Laser Catheter
- Where
- Colombia
- Sponsor
- Spectranetics Corporation
Coronary Artery Stenosis
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare…
- Trial name
- BLAST (NCT00739466)
- Testing
- Liposomal Alendronate
- Where
- 12 sites in Israel
- Volunteers
- 226 people
- Sponsor
- BIOrest Ltd.
In-Stent Restenosis
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length…
- Trial name
- AGENT IDE (NCT06492174)
- Testing
- AGENT DCB 40 mm
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Artery Disease
SONICURE（SONICracker for the Treatment of UndeRExpansion）
The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery.
- Trial name
- NCT06924736
- Testing
- Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter, Non - compliant balloon dilatation catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease
The Intra-Drug Eluting Stent (DES) Restenosis Study
A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.
- Trial name
- CRISTAL (NCT00323895)
- Testing
- drug-eluting stent and balloon angioplasty, drug-eluting stent
- Where
- 2 sites in France
- Volunteers
- 320 people
- Sponsor
- Cordis US Corp.
Peripheral Arterial Disease
DEFINITIVE AR Two Year Follow-up Extension Study
The purpose of this DEFINITIVE AR Two Year Follow-up Extension Study is to gather data to assess and estimate the long term effect of treating a vessel with plaque excision (PE) in combination with paclitaxel-coated balloon…
- Trial name
- NCT02363894
- Volunteers
- 53 people
- Sponsor
- Medtronic Endovascular
Dialysis; Complications, Central Vein Obstruction
APERTO CVS PMCF Study
Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients
- Conditions
- Dialysis; Complications, Central Vein Obstruction, Stenosis, Restenosis
- Trial name
- APERTO CVS (NCT04514406)
- Testing
- APERTO OTW DCB
- Where
- 2 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Cardionovum GmbH
Vascular Disease, Peripheral
Prevention of Restenosis Following Revascularization
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
- Trial name
- NCT00518284
- Testing
- Nanoparticle Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Coronary Artery Disease
A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)
The objectives of this study are: 1. To show a reduction in the late thrombosis (LT) rate following percutaneous revascularization using current interventional techniques with new stent placement and intravascular radiation…
- Trial name
- NCT00232778
- Testing
- GAMMA-Iridium-192 catheter
- Volunteers
- 579 people
- Sponsor
- Cordis US Corp.
Coronary Disease, Coronary Artery Disease
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT00180466
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 697 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, In Stent Restenosis
Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
This is a prospective, multicenter, randomized controlled clinical trial, which plans to enroll 260 subjects.
- Trial name
- SIBLINT ISR (NCT04240444)
- Testing
- drug-coated balloon Catheter
- Where
- 16 sites in China
- Volunteers
- 260 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Coronary Disease, Coronary Artery Disease
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT01171820
- Testing
- TAXUS® Liberté™, XIENCE V® EECSS
- Where
- 28 sites in Austria, France and 9 more
- Volunteers
- 324 people
- Sponsor
- Abbott Medical Devices
Instent Restenosis
The Valentines Trial
The primary objective of this multi-center, international, short term registry is to assess clinical success and efficacy of the paclitaxel eluting balloon treatment for in-stent restenosis at 6-9 months follow up.
- Trial name
- NCT01066832
- Testing
- Paclitaxel
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 276 people
- Sponsor
- Eurocor GmbH
Diabetes Mellitus, Type 2, Coronary Restenosis
Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
The purpose of this clinical research study is determine if patients with diabetes that have undergone previous opening of a heart blockage may have a blockage that is not causing any symptoms that may be detected by imaging with…
- Trial name
- NCT00162357
- Testing
- Technetium Tc99m Sestamibi
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease, Arterial Occlusive Diseases
The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions
To demonstrate the safety and efficacy of the Driver Coronary Stent coated with 10 mcg/mm ABT-578 compared to the uncoated Driver Stent for the treatment of single de novo lesions in native coronary arteries 2.25-3.5 mm in…
- Conditions
- Coronary Artery Disease, Arterial Occlusive Diseases, Coronary Disease, Coronary Arteriosclerosis
- Trial name
- ENDEAVOR II (NCT00614848)
- Testing
- Endeavor drug eluting coronary stent
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Medtronic Vascular
Patients Undergoing Repeat Peripheral Artery Revascularization
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.
The purpose of this study is to determine if CV-18C3 will reduce the rate of restenosis or the time to restenosis in patients undergoing repeat peripheral artery revascularization versus controls randomized to standard of care.
- Trial name
- NCT01270945
- Testing
- CV-18C3, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Janssen Research & Development, LLC
Myocardial Ischemia, Coronary Artery Stenosis
Safety Study of a Bioresorbable Coronary Stent
To evaluate the safety of a new bioresorbable (non-permanent) stent platform in native coronary arteries.
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- RESTORE (NCT01262703)
- Testing
- ReZolve Stent
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- REVA Medical, Inc.
Coronary Disease, Coronary Artery Disease
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels
The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB UK (NCT01977534)
- Testing
- Absorb BVS
- Where
- 24 sites in United Kingdom
- Volunteers
- 1,005 people
- Sponsor
- Abbott Medical Devices